Cargando…

Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania

Treating Kaposi sarcoma (KS) in children, adolescents, and young adults (AYA) remains a challenge in low- and middle-income countries (LMIC) where chemotherapy options and availability are limited. We describe a retrospective cohort review of pediatric patients with KS treated with paclitaxel in Mbe...

Descripción completa

Detalles Bibliográficos
Autores principales: Adinani, Hamidu, Campbell, Liane, El-Mallawany, Nader Kim, Slone, Jeremy, Mehta, Parth, Bacha, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067189/
https://www.ncbi.nlm.nih.gov/pubmed/33918352
http://dx.doi.org/10.3390/children8040275
_version_ 1783682744358797312
author Adinani, Hamidu
Campbell, Liane
El-Mallawany, Nader Kim
Slone, Jeremy
Mehta, Parth
Bacha, Jason
author_facet Adinani, Hamidu
Campbell, Liane
El-Mallawany, Nader Kim
Slone, Jeremy
Mehta, Parth
Bacha, Jason
author_sort Adinani, Hamidu
collection PubMed
description Treating Kaposi sarcoma (KS) in children, adolescents, and young adults (AYA) remains a challenge in low- and middle-income countries (LMIC) where chemotherapy options and availability are limited. We describe a retrospective cohort review of pediatric patients with KS treated with paclitaxel in Mbeya, Tanzania, between 1 March 2011 and 31 December 2019. Paclitaxel was given to patients who had KS relapse, a contraindication to bleomycin, vincristine, and doxorubicin (ABV), special circumstances in which a clinician determined that paclitaxel was preferable to ABV, or experienced treatment failure, defined as persistent KS symptoms at the completion of treatment. All patients also received multidisciplinary palliative care. Seventeen patients aged 5.1–21.3 years received paclitaxel, of whom 47.1% (8/17) had treatment failure, 29.4% (5/17) received paclitaxel as initial treatment, and 23.5% (4/17) had relapsed. All HIV positive patients (16/17) were given anti-retroviral therapy (ART) and 87.5% (14/16) achieved viral load <1000 cp/mL. At censure, 82.3% (14/17) of patients were alive—71.4% (10/14) achieved complete clinical remission and 28.6% (4/14) achieved a partial response. The median follow up was 37.3 months (range 8.0–83.5, IQR 19.7–41.6), and no patients were lost to follow up. In this cohort, high rates of long-term survival and favorable outcomes were possible with paclitaxel treatment.
format Online
Article
Text
id pubmed-8067189
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80671892021-04-25 Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania Adinani, Hamidu Campbell, Liane El-Mallawany, Nader Kim Slone, Jeremy Mehta, Parth Bacha, Jason Children (Basel) Article Treating Kaposi sarcoma (KS) in children, adolescents, and young adults (AYA) remains a challenge in low- and middle-income countries (LMIC) where chemotherapy options and availability are limited. We describe a retrospective cohort review of pediatric patients with KS treated with paclitaxel in Mbeya, Tanzania, between 1 March 2011 and 31 December 2019. Paclitaxel was given to patients who had KS relapse, a contraindication to bleomycin, vincristine, and doxorubicin (ABV), special circumstances in which a clinician determined that paclitaxel was preferable to ABV, or experienced treatment failure, defined as persistent KS symptoms at the completion of treatment. All patients also received multidisciplinary palliative care. Seventeen patients aged 5.1–21.3 years received paclitaxel, of whom 47.1% (8/17) had treatment failure, 29.4% (5/17) received paclitaxel as initial treatment, and 23.5% (4/17) had relapsed. All HIV positive patients (16/17) were given anti-retroviral therapy (ART) and 87.5% (14/16) achieved viral load <1000 cp/mL. At censure, 82.3% (14/17) of patients were alive—71.4% (10/14) achieved complete clinical remission and 28.6% (4/14) achieved a partial response. The median follow up was 37.3 months (range 8.0–83.5, IQR 19.7–41.6), and no patients were lost to follow up. In this cohort, high rates of long-term survival and favorable outcomes were possible with paclitaxel treatment. MDPI 2021-04-02 /pmc/articles/PMC8067189/ /pubmed/33918352 http://dx.doi.org/10.3390/children8040275 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Adinani, Hamidu
Campbell, Liane
El-Mallawany, Nader Kim
Slone, Jeremy
Mehta, Parth
Bacha, Jason
Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title_full Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title_fullStr Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title_full_unstemmed Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title_short Use of Paclitaxel to Successfully Treat Children, Adolescents, and Young Adults with Kaposi Sarcoma in Southwestern Tanzania
title_sort use of paclitaxel to successfully treat children, adolescents, and young adults with kaposi sarcoma in southwestern tanzania
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067189/
https://www.ncbi.nlm.nih.gov/pubmed/33918352
http://dx.doi.org/10.3390/children8040275
work_keys_str_mv AT adinanihamidu useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania
AT campbellliane useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania
AT elmallawanynaderkim useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania
AT slonejeremy useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania
AT mehtaparth useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania
AT bachajason useofpaclitaxeltosuccessfullytreatchildrenadolescentsandyoungadultswithkaposisarcomainsouthwesterntanzania